Innovodigm Secures Rs 5.5 Crore to Launch Needle-Free, Heat-Stable Vaccines
- Innovodigm raises Rs 5.5 Crore in seed funding led by Indian Angel Network.
- Developing needle-free, thermostable vaccine patches that work up to 40°C.
- Clinical trials to begin in 2026; tech selected as Top 2 at Nano Electronics Showcase 2025.
Innovodigm, a medtech firm that leads in needle-free vaccine delivery, has received Rs 5.5 crore of seed capital, with the Indian Angel Network (IAN) contributing Rs 4.5 crore as the lead investor. The rest of the capital was contributed by PadUp Ventures.
The funds will be utilized to increase infrastructure, streamline internal processes, and hire more members as the startup prepares for third-party preclinical validations and subsequent clinical trials.
Innovodigm was established in 2020 by Jhimli Manna and Ayan Chatterjee and is creating an advanced Microneedle Array Patch (MAP) platform. The needle-free device administers thermostable vaccines using micro-array patches that last for 120 days at 40°C providing a strong alternative for injectable cold-chain-dependent vaccines. The technology not only decreases the requirement for refrigeration but also the medical waste, making it a good fit for deployment in under-resourced areas.
Resulting from IIT Kharagpur's Microelectronics and MEMS Lab, Innovodigm combines biomedical engineering with public health objectives, aiming at scalable and low-cost vaccine delivery for local and international markets. The firm has already received notice being chosen as one of the Top 2 Technologies at the Ministry of Electronics and IT's Nano Electronics Showcase 2025.
In a significant turn of events, Innovodigm has executed an Material Transfer Agreement (MTA) with a top Indian vaccine developer for third-party validation of its MAP platform, with human clinical trials to start in 2026.
Also Read: Kruu Raises Rs 1 Crore in Bridge Round to Scale Global Skilling Platform
Innovodigm intends to increase its application of its MAP platform to vaccines for diseases like measles, hepatitis, flu, and COVID-19 boosters. The company plans to set up decentralized manufacturing centers in the future to localize production and disrupt supply chain bottlenecks especially across low- and middle-income nations.
By making technology converge with healthcare equity, Innovodigm can transform the delivery, storage, and accessibility of vaccines around the world.
